Medpace Inc. (MEDP)
NASDAQ: MEDP
· Real-Time Price · USD
486.98
4.64 (0.96%)
At close: Sep 05, 2025, 3:59 PM
486.98
0.00%
After-hours: Sep 05, 2025, 04:34 PM EDT
Medpace Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antiviral And Anti Infective Revenue | 29.11M | 31.06M | 34.84M | 38.38M | 39.2M | 44.03M | 48.89M | 45.55M | 36.01M | 32.87M | 29.69M | 31.45M | 25.58M | 31.32M | 26.93M | 27.03M | 26.19M | 30.82M | 27.24M | 22.99M | 25.15M | 19.56M | 24.24M | 22.66M | 19.92M | 17.78M | 16.68M |
| Antiviral And Anti Infective Revenue Growth | -6.30% | -10.85% | -9.23% | -2.08% | -10.98% | -9.94% | +7.35% | +26.49% | +9.56% | +10.69% | -5.58% | +22.94% | -18.33% | +16.28% | -0.37% | +3.21% | -15.02% | +13.13% | +18.51% | -8.59% | +28.57% | -19.32% | +6.97% | +13.75% | +12.08% | +6.58% | n/a |
| Cardiology Revenue | 58.58M | 58.28M | 58.3M | 55.81M | 60.7M | 55.64M | 51.58M | 44.36M | 51.13M | 46.62M | 45.41M | 49.8M | 42.03M | 37.4M | 33.15M | 34.74M | 28.04M | 23.76M | 27.59M | 21.75M | 25.9M | 22.47M | 21.73M | 22.14M | 20.42M | 22.52M | 23.74M |
| Cardiology Revenue Growth | +0.52% | -0.04% | +4.46% | -8.05% | +9.10% | +7.86% | +16.28% | -13.24% | +9.68% | +2.66% | -8.82% | +18.50% | +12.38% | +12.79% | -4.55% | +23.88% | +18.00% | -13.88% | +26.84% | -16.00% | +15.28% | +3.37% | -1.84% | +8.41% | -9.31% | -5.12% | n/a |
| Central Nervous System Revenue | 61.13M | 54.9M | 49.22M | 42.1M | 46.52M | 44.14M | 39.65M | 43.99M | 37.73M | 38.7M | 37.13M | 43.42M | 38.91M | 38.49M | 35.33M | 32.85M | 28.55M | 24.81M | 21.75M | 19.22M | 23.98M | 17.05M | 16.33M | 16.79M | 14.87M | 13.8M | 13.16M |
| Central Nervous System Revenue Growth | +11.34% | +11.53% | +16.93% | -9.50% | +5.40% | +11.33% | -9.88% | +16.60% | -2.51% | +4.23% | -14.49% | +11.60% | +1.09% | +8.93% | +7.54% | +15.07% | +15.07% | +14.10% | +13.15% | -19.85% | +40.66% | +4.38% | -2.73% | +12.92% | +7.75% | +4.82% | n/a |
| Metabolic Revenue | 147.87M | 148.01M | 122.87M | 124.73M | 106.3M | 103.64M | 99.02M | 103.12M | 87.86M | 86.84M | 77.49M | 63.48M | 55.6M | 48.12M | 47.13M | 42.13M | 38.14M | 32.49M | 29.62M | 30.21M | 36.08M | 36.36M | 34.92M | 31.49M | 33.74M | 26.25M | 22.05M |
| Metabolic Revenue Growth | -0.10% | +20.47% | -1.50% | +17.34% | +2.57% | +4.66% | -3.97% | +17.37% | +1.17% | +12.07% | +22.07% | +14.17% | +15.55% | +2.09% | +11.86% | +10.46% | +17.38% | +9.72% | -1.96% | -16.26% | -0.79% | +4.14% | +10.89% | -6.68% | +28.55% | +19.01% | n/a |
| Oncology Revenue | 188.56M | 170.48M | 168.17M | 164.92M | 162.95M | 155.2M | 148.73M | 149.33M | 147.09M | 141.95M | 124.21M | 122.83M | 115.54M | 105.21M | 95.74M | 94.72M | 93.25M | 79.14M | 68.63M | 65.63M | 69.21M | 70.61M | 65.53M | 64.62M | 55.96M | 53.23M | 43.85M |
| Oncology Revenue Growth | +10.61% | +1.37% | +1.97% | +1.21% | +5.00% | +4.35% | -0.40% | +1.52% | +3.62% | +14.29% | +1.12% | +6.31% | +9.82% | +9.90% | +1.07% | +1.58% | +17.83% | +15.31% | +4.58% | -5.18% | -1.99% | +7.76% | +1.41% | +15.47% | +5.13% | +21.39% | n/a |
| Other Revenue | 118.06M | 95.84M | 103.18M | 107.37M | 112.43M | 108.4M | 110.53M | 106.16M | 101.06M | 87.1M | 80.17M | 72.77M | 73.56M | 70.42M | 70.27M | 64.09M | 64.12M | 68.94M | 55.54M | 45.2M | 50.57M | 63.84M | 53.48M | 51.94M | 51.32M | 48.45M | 34.22M |
| Other Revenue Growth | +23.19% | -7.12% | -3.90% | -4.50% | +3.72% | -1.92% | +4.11% | +5.05% | +16.02% | +8.64% | +10.18% | -1.07% | +4.46% | +0.21% | +9.64% | -0.05% | -6.99% | +24.12% | +22.89% | -10.63% | -20.79% | +19.36% | +2.97% | +1.22% | +5.91% | +41.61% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 46.66M | 57.9M | 45.43M | 49.22M | 41.45M | 44.08M | 42.51M | 41.41M | 39.4M | 38.03M | 33.4M | 35.42M | 33.22M | 29.37M | 27.66M | 28.05M | 26.97M | 25.74M | 22.38M | 22.8M | 21.86M | 25.12M | 21.26M | 29.12M | 23.56M | 21.31M | 20.57M | 18.61M | 20.51M | 16M | 16.84M | 16.61M | 14.76M | 15.15M | 16.78M | 16.39M | 14.82M | 13.51M | 18.25M | 15.29M | 11.71M | 11.74M |
| Selling, General, and Administrative Revenue Growth | -19.40% | +27.43% | -7.69% | +18.73% | -5.96% | +3.69% | +2.67% | +5.08% | +3.62% | +13.85% | -5.69% | +6.63% | +13.11% | +6.15% | -1.36% | +3.98% | +4.80% | +15.00% | -1.82% | +4.31% | -13.01% | +18.17% | -26.99% | +23.62% | +10.55% | +3.59% | +10.55% | -9.27% | +28.18% | -5.01% | +1.42% | +12.54% | -2.63% | -9.71% | +2.39% | +10.57% | +9.73% | -26.00% | +19.35% | +30.66% | -0.31% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |